Immunotherapy in NSCLC
|
|
- Eustacia Ford
- 5 years ago
- Views:
Transcription
1 Immunotherapy in NSCLC Enriqueta Felip Hospital Vall d Hebron University, Barcelona SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, January
2 Immunotherapy in NSCLC: Outline 1 st line as monotherapy 1 st line in combination with anti-ctla4 / CT New combinations Neoadjuvant / adjuvant setting
3 Checkmate 26: Phase III Nivolumab vs Chemotherapy in First-line NSCLC Key Eligibility Criteria Stage IV or recurrent NSCLC No prior systemic therapy for advanced disease No EGFR/ALK mutations sensitive to available targeted inhibitor therapy 1% PD-L1 a CNS metastases if treated prior to randomization, with return to baseline for at least 2 weeks prior to randomization Stratification factors at randomization: PD-L1 expression (<5% vs 5%) a Histology (squamous vs nonsquamous) R 1:1 Nivolumab 3 mg/kg IV Q2W n=271 PT-DC (Histology dependent) b Maximum of 6 cycles n=27 Primary Endpoint: PFS ( 5% PD-L1+) d Tumor scans Q6W until wk 48 then Q12W Disease Progression Disease progression or unacceptable toxicity Secondary Endpoints: Crossover nivolumab c (optional) PFS ( 1% PD-L1+) d OS ( 1% PD-L1+ and 5% PD-L1+) ORR ( 5% PD-L1+) d Socinski M et al. Oral presentation at ESMO 216
4 Checkmate 26: PFS and OS ( 5% PD-L1+) 1 8 Median PFS, mos (95% CI) Nivolumab n = (3., 5.6) Chemo n = (5.4, 6.9) 1-year PFS rate, % Median OS, mos (95% CI) Nivolumab n = (11.7, 17.4) Chemo n = (1.7, 17.1) 1-year OS rate, % PFS (%) 6 4 HR = 1.15 (95% CI:.91, 1.45), P =.2511 OS (%) 6 4 HR = 1.2 (95% CI:.8, 1.3) Chemotherapy 2 Nivolumab 2 Months Chemotherapy No. of patients at risk: Nivo CT Nivolumab Months No. of patients at risk: Nivo CT All randomized patients ( 1% PD-L1+) HR = 1.17 (95% CI:.95, 1.43) All randomized patients ( 1% PD-L1+) HR = 1.7 (95% CI:.86, 1.33) Socinski M et al. Oral presentation at ESMO 216
5 Checkmate 26: Safety summary Treatment-related AEs, % Any AEs Select AEs AEs leading to discontinuation Nivolumab (n = 267) Any grade Grade Chemotherapy (n = 263) Any grade Grade Treatment-related deaths, n (%) 2 (.7) 3 (1.1) Treatment-related select AEs, % e Any grade Grade 3 4 Any grade Grade 3 4 Skin Gastrointestinal Hepatic Pulmonary Hypersensitivity/infusion reaction Renal Socinski M et al. Oral presentation at ESMO 216
6 KEYNOTE-24: Study design A Phase III, randomized, open-label study of pembrolizumab vs platinum-doublet chemotherapy as firstline therapy in patients with advanced or metastatic NSCLC that expresses PD-L1 in 5% of tumor cells N=35 Key Inclusion Criteria Advanced or metastatic, previously untreated NSCLC PD-L1+ tumor expression 5% No EGFR sensitizing mutation or ALK translocation ECOG PS 1 Primary endpoint: PFS (RECIST v1.1 per blinded, independent central review) Secondary endpoints: ORR, OS, safety, and tolerability Exploratory endpoint: DOR R 1:1 Pembrolizumab 2 mg Q3W (2 years) Optional crossover after disease progression Investigator choice of platinum-based chemotherapy For 4 6 cycles Reck M et al. N Engl J Med. 216
7 KEYNOTE-24: PD-L1 Screening 1934 patients entered screening 1729 submitted samples for PD-L1 assessment 1653 samples evaluable for PD-L1 5 TPS 5% (3%) 1153 TPS <5% Reck M et al. N Engl J Med. 216.
8 KEYNOTE-24: PFS and OS (PD-L1 5%) 1 8 Events, n Median, mo HR (95% CI) Pembro Chemo ( ) P < % 72% 7% 54% PFS, % % 15% 2 62% 5% No. at risk Time (months) OS, % No. at risk Pembr o Events, n 44 Median, mo NR Chemo 64 NR HR (95% CI).6 ( ) Time (months) P.5 Reck M et al. N Engl J Med. 216
9 KEYNOTE-24: Exposure and TRAE Summary Exposure, median (range) Pembrolizumab N = mo (1 d 18.7 mo) Chemotherapy N = mo (1 d 16.8 mo) TRAEs, n (%) 113 (73.4) 135 (9.) Grade (26.6) 8 (53.3) Serious 33 (21.4) 31 (2.7) Led to discontinuation 11 (7.1) 16 (1.7) Led to death 1 (.6) 3 (2.). Reck M et al. N Engl J Med. 216.
10 Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS 5%: Data from KEYNOTE-24 Pembrolizumab was associated with a significantly greater improvement from baseline to Week 15 in HRQoL vs. platinum-doublet (difference in LS mean 7.8 [95%CI 2.8, 12.8], p=.2) Pembrolizumab showed slower deterioration in HRQoL due to symptoms (p=.29) Time to deterioration (EORTC QLQ-LC13 composite endpoint of cough, chest pain and dyspnea) Time to deterioration (survival analysis) Events, n (%) HR (95%CI) Pembro (n=51) 46 (3.5).66 (.44,.97) Chemo (n=148) 58 (39.2) p= Time, months Brahmer et al. J Thorac Oncol 216; 11(suppl): abstr PL4a.1
11 CheckMate % PD-L1 expression level mos (mos) Nivo 17.7 Doc % PD-L1 expression level mos (mos) Nivo 19.4 Doc % PD-L1 expression level mos (mos) Nivo 19.9 Doc OS (%) Nivo Doc HR (95% CI) =.58 (.43,.79) Time (mos) 3 1 HR (95% CI) =.43 (.3,.62) Time (mos) 3 1 HR (95% CI) =.4 (.27,.58) Time (mos) <1% PD-L1 expression level mos (mos) Nivo 1.5 Doc <5% PD-L1 expression level mos (mos) Nivo 9.8 Doc <1% PD-L1 expression level mos (mos) Nivo 9.9 Doc OS (%) Nivo Doc Time (mos) Based on a July 2, 215 DBL. Symbols represent censored observations HR (95% CI) =.87 (.63, 1.19) HR (95% CI) =.96 (.73, 1.27) HR (95% CI) =.96 (.74, 1.25) Time (mos) Time (mos) 3
12 OAK, OS, PD-L1 Expression on 5% TC or 1% IC TC3 or IC3; 16% of patients Overall Survival, % Atezolizumab Docetaxel Median 8.9 mo (95% CI, 5.6, 11.6) HR,.41 a (95% CI,.27,.64) P<.1 b Minimum follow-up = 19 months Median 2.5 mo (95% CI, 17.5, NE) Months a Unstratified HR. b P values for descriptive purpose only. Barlesi F, et al. Ann Oncol. 216;27(suppl 6): Abstract LBA44.
13 495 locally or metastatic NSCLC pts biopsy Pembrolizumab 2 or 1 mg/ Kg q 3 w or 1 mg/k q 2 w
14 PFS and OS Subgroup Analyses CheckMate 26: Nivolumab vs Chemotherapy in First-Line NSCLC Patients, n Unstratified HR Unstratified HR (95% CI) Subgroup Nivolumab Chemotherapy PFS OS PFS OS Overall years <65 years Male Female ECOG PS = ECOG PS Squamous Non-squamous Never smoker Former smoker Current smoker % PD-L Nivolumab Chemotherapy Nivolumab Chemotherapy Socinski MA, et al. Ann Oncol. 216;27(suppl 6): Abstract LBA7.
15 NEW STANDARD IN FRONT LINE THERAPY FOR ADVANCED NSCLC EGFR 12-15% ALK 3-5% ROS1 1% PD-L1 ~15% For PD-L1 >5%, pembrolizumab
16
17 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1 Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study Study objective To evaluate atezolizumab monotherapy in PD-L1-selected advanced NSCLC patients results from Cohort 1 of the phase 2 BIRCH trial Key patient inclusion criteria Locally advanced or metastatic NSCLC Tumour PD-L1 expression by IHC (TC2/3 and/or IC2/3 No brain metastases ECOG PS or 1 (n=667) Primary endpoint ORR (RECIST v1.1) R Cohort 1 (1L) No prior chemo Atezolizumab 12 mg IV q3w (n=138) Cohort 2 (21L) 1 prior platinum chemo Atezolizumab 12 mg IV q3w (n=271) Cohort 3 (3L+) 2 prior chemo (incl. 1 platinum) Atezolizumab 12 mg IV q3w (n=254) Secondary endpoints PFS, DoR, OS, safety PD Loss of clinical benefit Loss of clinical benefit Garassino et al. J Thorac Oncol 216; 11(suppl): abstr OA3.2
18 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1 Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study Frequency, % Key results 49% 42% 34% 34% 25% 18% CR/PR TC3 or IC3 TC2/3 or IC2/3 TC2 and IC2 SD In patients with advanced NSCLC, atezolizumab showed promising efficacy and had a similar safety profile to previous atezolizumab studies TC3 or IC3 = TC 5% or IC 1% PD-L1 expressing cells; TC2 and IC2 = 5% but IC <1% and TC <5% PD-L1 expressing cells; TC2/3 or IC2/3 = TC or IC 5% PD-L1 expressing cells, respectively. Safety summary, n (%) n=138 Total patients with 1 AE 126 (91) Grade 5 2 (1) AEs led to dose interruption 39 (28) TRAEs 83 (6) Grade 5 TRAEs led to withdrawal 5 (4) SAEs 45 (33) TC3 or IC3 (n = 65) TC2/3 or IC2/3 (n = 138) TC2 and IC2 (n = 73) mos, months (95%CI) 26.9 (12., NE) 23.5 (18.1, NE) 23.5 (18.1, NE) 1-year OS rate, % (95%CI) 61.5 (49., 74.) 66.4 (58.1, 74.6) 7.7 (59.8, 81.6) Garassino et al. J Thorac Oncol 216; 11(suppl): abstr OA3.2
19 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti- PD-L1) as First-Line Treatment in Patients with Advanced NSCLC Study objective To evaluate the safety and clinical activity of avelumab as first-line therapy in a cohort of patients with NSCLC (dose expansion phase, 1b) Methods Patients with stage IV or recurrent NSCLC with no prior treatment received avelumab 1 mg/kg IV (1 h) q2w Key results 16 (1.3%) patients had a potentially immune-related TRAE; grade 3 adrenal insufficiency in 1 (.6%) patient only. No grade 3 4 pneumonitis; grade 1 2 pneumonitis in 4 (2.6%) patients and 11 (7.1%) patients discontinued treatment following a TRAE mpfs 17.6 weeks (95%CI 11.6, 23.6) with 24-week PFS rate of 37.2% ORR 22.4% (95%CI 16.2, 29.8) and DCR 65.4%. ORR was higher in those aged 65 years, females and ECOG PS Conclusion Early results indicate that avelumab has a durable anti-tumour activity and is well tolerated Verschraegen et al. J Thorac Oncol 216; 11(suppl): abstr OA3.3
20 IMpower 11 and JAVeLIN lung 1: Study designs Phase III, open-label trials of anti PD-L1 vs Pt-based doublet chemotherapy for first-line treatment of stage IV, PD-L1 positive NSCLC IMPOWER 11 1,2 N=57 Key Inclusion Criteria Stage IV NSCLC Treatment-naïve PD-L1 positive TC and IC ECOG PS 1 Primary Endpoints: PFS Study Sponsor: Roche R 1:1 Atezolizumab NSQ Pemetrexed + cisplatin/carboplatin SQ Gemcitabine + cisplatin/carboplatin Until disease progression, unacceptable toxicity, or death JAVELIN LUNG 1 3 N=42 Key Inclusion Criteria Stage IV or recurrent NSCLC Treatment-naïve PD-L1 positive tumor ECOG PS 1 Primary Endpoints: PFS, OS Study Sponsor: Pfizer R Avelumab NSQ Pemetrexed + cisplatin/carboplatin SQ Paclitaxel + carboplatin, or gemcitabine + cisplatin/carboplatin Until disease progression, unacceptable toxicity, or death. Clinicaltrials.gov. NCT Accessed September 8, Herbst RS et al. Poster presented at ESMO Asia TiP. 3. Clinicaltrials.gov. NCT Accessed September 8,
21 Checkmate 12 (Nivo ± IPI arms): study design Stage IIIB/IV NSCLC (any histology), no prior chemotherapy for advanced disease, ECOG PS or 1 Nivolumab 3 mg/kg IV Q2W a Nivolumab 3 mg/kg IV Q2W + Ipilimumab 1 mg/kg IV Q12W b Nivolumab 3 mg/kg IV Q2W + Ipilimumab 1 mg/kg IV Q6W b Until disease progression c or unacceptable toxicity Primary endpoint: safety and tolerability Secondary endpoints: ORR (RECIST v1.1) and PFS rate at 24 weeks Exploratory endpoints: OS, efficacy by PD-L1 expression
22 Checkmate 12: 1L Nivolumab ± Ipilimumab: Efficacy by Tumor PD-L1 Expression 1 8 Nivo 3 Q2W + Ipi 1 Q6/12W 92 ORR (%) n Overall <1% 1% 5% PD-L1 expression 5 CRs (1%) were achieved in the nivolumab monotherapy cohort (1 in a patient with tumor PD-L1 expression <1%) 6 CRs (8%) were achieved in the nivolumab + ipilimumab cohorts a (3 in patients with tumor PD- L1 expression <1%)
23 Checkmate 12: 1L Nivolumab ± Ipilimumab: PFS by tumor PD-L1 expression Nivo 3 Q2W + Ipi 1 Q6/12W PFS (%) All treated patients (n = 77) 1% PD-L1 (n = 46) 5% PD-L1 (n = 13) 1 Median 8. mo (95% CI 4.1, 13.2) Median 12.7 mo (95% CI 7.8, 23.) Median NR (95% CI 7.8, NR) Months Months Months All treated patients (n = 52) 1% PD-L1 (n = 32) 5% PD-L1 (n = 12) Nivo 3 Q2W PFS (%) Median 3.6 mo (95% CI 2.3, 6.6) Median 3.5 mo (95% CI 2.2, 6.6) Median 8.3 mo (95% CI 2.2, NR) Months Months Months 23
24 Checkmate 12: 1L Nivolumab ± Ipilimumab safety summary Nivo 3 Q2W (n = 52) Any grade Grade 3 4 Nivo 3 Q2W + Ipi 1 Q12W (n = 38) Any grade Grade 3 4 Nivo 3 Q2W + Ipi 1 Q6W (n = 39) Any grade Grade 3 4 Treatment-related AEs, % Treatment-related AEs leading to discontinuation, % There were no treatment-related deaths After an additional 6 months of follow-up in the Q12W and Q6W combination cohorts, rates of treatment-related AEs with nivolumab + ipilimumab remained similar to those previously reported Hellmann MD, et al. Lancet Oncol 216 Dec 5. [Epub ahead of print].
25 Checkmate 227: Study Design Key Inclusion Criteria: Stage IV or recurrent NSCLC No prior systemic therapy for advanced disease No EGFR/ALK mutations sensitive to available targeted inhibitor therapy R 1:1:1 PD-L1+ ( 1%) Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W Nivolumab monotherapy 24 mg Q2W Chemotherapy Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W Tumor scans Q6W until week 48 then Q12W Disease progression or unacceptabl e toxicity CNS metastases permitted if adequately treated 2 weeks prior to randomization PD-L1- (<1%) Nivolumab 36 mg Q3W + Chemotherapy Chemotherapy Stratification Factor Randomization: Histology (squamous vs non-squamous) Clinicaltrials.gov. NCT (CheckMate 227)
26 Durvalumab + tremelimumab: Phase Ib study design N=12 Key Inclusion Criteria Immunotherapy-naïve 1 line of prior therapy Locally advanced or metastatic NSCLC ECOG PS 1 Primary objectives: Safety, DLT/MTD Secondary objectives: ORR, PK, disease control at 24 weeks, immunogenicity Dose escalation for 12 months T1 Cohort Durvalumab 3 2 mg/kg Q4/2W* Tremelimumab 1 mg/kg Q4W x6 then Q12W x3 T3 Cohort Durvalumab 1 2 mg/kg Q4/2W* Tremelimumab 3 mg/kg Q4W x6 then Q12W x3 T1 Cohort Durvalumab 15 mg/kg Q4W Tremelimumab 1 mg/kg Q4W x6 then Q12W x3 ORR PD-L1 status All patients PD-L1 expression D1 2 Q4/2W (T1) D1 2 Q4/2W (T3) D15 Q4W (T1) D1 Q2W monotherapy n/n (%) n/n (%) n/n (%) n/n (%) 6/26 (23) 5/25 (2) /9 () 32/2 (16) 25% 2/9 (22) 2/5 (4) /4 () 23/84 (27) <25% 4/14 (29) 2/17 (12) /4 () 5/92 (5) % 4/1 (4) 1/1 (1) /3 () 1/33 (3) Phase III dose identified: durvalumab 2 mg/kg plus tremelimumab 1 mg/kg Q4W Antonia S et al. Lancet Oncol. 216;17(3):299-38
27 MYSTIC: Study Design Phase III, open-label, first-line therapy study of durvalumab ± tremelimumab vs SOC in NSCLC N=192 Key Inclusion Criteria Treatment-naïve Evidence of Stage IV NSCLC No activating EGFR or ALK rearrangement ECOG PS 1 No mixed SCLC or NSCLC NOS No prior immunomodulatory therapy No brain metastases/spinal cord compression unless asymptomatic, treated, and stable No active or prior documented inflammatory bowel disease R 1:1:1 Durvalumab 2 mg/kg Q4W + tremelimumab 1 mg/kg Q4W Durvalumab 2 mg/kg Q4W Platinum-doublet chemotherapy Paclitaxel + carboplatin Pemetrexed + cisplatin or carboplatin Gemcitabine + cisplatin or carboplatin Primary Endpoints: OS, PFS (combination vs SOC). Clinicaltrials.gov. NCT
28 NEPTUNE: Study Design Phase III, open-label, global study of durvalumab in combination with tremelimumab vs Pt-based chemotherapy in first-line treatment of advanced or metastatic NSCLC N=8 Key Inclusion Criteria Treatment-naïve Evidence of Stage IV NSCLC No activating EGFR or ALK rearrangement PD-L1 positive* or negative ECOG PS or 1 No mixed SCLC or NSCLC NOS No brain metastases/spinal cord compression unless asymptomatic, treated, and stable No active or prior documented inflammatory bowel disease Primary Endpoint: OS R Durvalumab 2 mg/kg Q4W + tremelimumab 1 mg/kg Q4W n=4 SOC Pt-based doublet chemotherapy Carboplatin + paclitaxel NSQ: Carboplatin/cisplatin + pemetrexed SQ: Carboplatin/cisplatin + gemcitabine n=4 Clinicaltrials.gov. NCT
29 CheckMate 12 (Nivo + chemo arms): study design An open-label, randomized, multi-arm, phase I trial of nivolumab in combination with chemotherapy or targeted agents, or as monotherapy in patients with Stage IIIb/IV NSCLC N=412 Key Inclusion Criteria Newly diagnosed and confirmed Stage IIIb/IV NSCLC ECOG PS 1 Chemotherapy naïve Prior EGFR TKI acceptable R Nivolumab 1 mg/kg Q3W Gemcitabine 125 mg/m 2 + cisplatin 75 mg/m 2 x4 Nivolumab 1 mg/kg Q3W Pemetrexed 5 mg/m 2 + cisplatin 75 mg/m 2 x4 Nivolumab 1 mg/kg Q3W Paclitaxel 2 mg/m 2 + carboplatin AUC 6 x4 Nivo Q3W Until progressive disease or discontinua tion due to toxicity Primary Outcome Measures: Safety and tolerability Secondary Outcome Measures: ORR PFS rate at 24 weeks Nivolumab 5 mg/kg Q3W Paclitaxel 2 mg/m 2 + carboplatin AUC 6 x4 Rizvi NA et al. J Clin Oncol216;34(25):
30 Checkmate 12: PFS and OS, nivo + chemo Group Median OS, months (range) 1-Year OS, % 2-Year OS, % Nivo 1 mg/kg + Gem-Cis 11.6 ( ) 5 25 Nivo 1 mg/kg + Pem-Cis 19.2 ( ) Nivo 1 mg/kg + Pac-Carb 14.9 ( ) 6 27 Nivo 5 mg/kg + Pac-Carb NR ( ) Group Median PFS, months (range) 24-Week PFS, % Nivo 1 mg/kg + Gem-Cis 5.7 ( ) 51 Nivo 1 mg/kg + Pem-Cis 6.8 ( ) 71 Nivo 1 mg/kg + Pac-Carb 4.8 ( ) 38 Nivo 5 mg/kg + Pac-Carb 7.1 ( ) 51 OS (%) Nivo 1 mg/kg + Gem-Cis Nivo 1 mg/kg + Pem-Cis Nivo 1 mg/kg + Pac-Carb Nivo 5 mg/kg + Pac-Carb PFS (%) Nivo 1 mg/kg + Gem-Cis Nivo 1 mg/kg + Pem-Cis Nivo 1 mg/kg + Pac-Carb Nivo 5 mg/kg + Pac-Carb Time Since First Dose (months) Time Since First Dose (months) Rizvi NA et al. J Clin Oncol. 216;24(25):
31 KEYNOTE-21: Study Design Key Eligibility Criteria Untreated stage IIIB or IV nonsquamous NSCLC No activating EGFR mutation or ALK translocation Provision of a sample for PD-L1 assessment a ECOG PS -1 No untreated brain metastases No ILD or pneumonitis requiring systemic steroids R (1:1) a N=1 23 Pembrolizumab 2 mg Q3W for 2 years + Carboplatin AUC 5 mg/ml/min + Pemetrexed 5 mg/m 2 Q3W for 4 cycles b Carboplatin AUC 5 mg/ml/min + Pemetrexed 5 mg/m 2 Q3W for 4 cycles b PD Pembrolizuma b 2 mg Q3W for 2 years Primary endpoint: ORR (RECIST v1.1 per blinded, independent central review) Secondary endpoints: PFS, OS, safety Exploratory endpoint: Relationship between antitumor activity and PD-L1 TPS Langer CJ et al. Oral presentation at ESMO 216. LBA46.
32 ORR, % (95% CI) % KEYNOTE-21: Response Δ26% P=.16 29% ORR, % (95% CI) % 54% ORR by PD-L1 expression level 8% 26% 13% 39% 35% 38% Pembrolizumab + Chemotherapy Chemotherapy Alone <1% n=21 1% n=39 1%-49% 5% n=19 n=2 <1% 1% 1%-49% n=23n=4 n=23 5% n=17 Pembrolizumab + Chemotherapy Chemotherapy Alone Langer CJ et al. Oral presentation at ESMO 216. LBA46.
33 KEYNOTE-21: PFS AND OS PFS, % Pembro + chemo Events, n Chemo alone 33 77% 63% HR (95% CI) (.31.91) 13. mo 8.9 mo P=.12 OS, % Pembro + chemo Events, n Chemo alone % 92 % HR (95% CI) 13.9 ( ) 75% 72% No. at risk Time, months No. at risk Time, months Langer CJ et al. Oral presentation at ESMO 216. LBA46.
34 KEYNOTE-21: SAFETY SUMMARY Exposure, median (range) Pembro + Chemo n=59 8. mo (1 d-16.1 mo) Chemo Alone n= mo (1 d-15.3 mo) Treatment-related AEs, n (%) 55 (93) 56 (9) Grade (39) 16 (26) Led to discontinuation 6 (1) 8 (13) Led to death 1 (2) 2 (3) Langer CJ et al. Oral presentation at ESMO 216. LBA46.
35 Immunotherapy, 1st line in wt patients NSCLC PD-L1 strong (> 5%) Pembrolizumab Ongoing studies CT vs CT+anti-PD1/PD-L1 CT vs CT+anti-PD1/PD-L1+bevacizumab CT vs anti-pd1 vs anti-pd1+anti-ctla4
36 Immunotherapy in stage IV A role in 1 st line treatment Anti-PD1/anti-PDL1 as monotherapy for selected populations (PDL1+); low percentage of patients Combination of anti-ctla4 + anti-pd1/anti-pdl1 for selected patients; toxicity may be an issue Combination of CT + anti-pd1/anti-pdl1; less relevance of predictive markers More predictive markers beyond PDL1 expected
37 Melero et al, Nature Reviews Cancer 15
38 JVDF (NCT ) Phase Ia/b Study Design Phase Ia: DLT Assessment (n = 6 to 12) Phase Ib: Cohort Expansion (n = 155) a Primary: Safety and tolerability Secondary: PK Primary: Safety and tolerability Secondary: PK and preliminary efficacy Exploratory: Biomarkers and immunogenicity Schedule 1: Gastric/GEJ, BTC design (n = 3 to 6) Ram 8 mg/kg, day 1 and 8 Pembro 2 mg fixed, day 1 Both IV every 3 weeks Schedule 2: Gastric/GEJ, NSCLC, UC design (n = 3 to 6) Ram 1 mg/kg, day 1 and 8 Pembro 2 mg fixed, day 1 Both IV every 3 weeks Interim Analysis Cohort A: 15 Gastric/GEJ (2 nd -3 rd Line) Cohort A1: 25 BTC (2 nd -3 rd Line) b Cohort A2: 25 Gastric/GEJ (1 st Line) b Cohort B: 15 Gastric/GEJ (2 nd -3 rd Line) Cohort C: 25 NSCLC (2 nd -4 th Line) Cohort D: 25 UC (2 nd -4 th Line) Cohort E: 25 NSCLC (1 st Line) b Final Analysis a Patients may continue treatment for up to 35 cycles, until confirmed progressive disease or discontinuation for any other reason. b Protocol was recently amended to add cohorts A1, A2, and E; cohorts are currently enrolling. DLT dose-limiting toxicity; PK, pharmacokinetics; Ram, ramucirumab; Pembro, pembrolizumab Herbst RS, et al. Ann Oncol. 216;27(suppl 6): Abstract LBA38.
39 Decreased Tumor Burden in NSCLC Patients (RECIST 1.1) Herbst RS, et al. Ann Oncol. 216;27(suppl 6): Abstract LBA38.
40 Progression-Free Survival by PD-L1 Status Herbst RS, et al. Ann Oncol. 216;27(suppl 6): Abstract LBA38.
41 Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous NSCLC Study objective To assess the safety and efficacy of necitumumab combined with pembrolizumab in patients with stage IV NSCLC Key patient inclusion criteria Stage IV NSCLC Progression after 1 platinumbased chemotherapy ECOG PS 1 (n=34) Necitumumab 6 mg or 8 mg IV D1, 8 q3w + pembrolizumab 2 mg IV D1 q3w PD/ toxicity/ death Primary endpoints Tolerability, ORR by RECIST 1.1 Secondary endpoints PFS Besse et al. J Thorac Oncol 216; 11(suppl): abstr MA9.11
42 Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous NSCLC Key results ORR for necitumumab + pembrolizumab was 29.4% and was effective in patients with differing PD-L1 expression Median PFS was 6.9 months (95%CI 2.7, NR) Toxicity for the combined regimen was no different to that for individual profiles Patients N/n ORR, % Patients n ORR, % Total Prior systemic therapy EGFR TKI in first line No EGFR TKI in first line Smoking history Current/former Never PD-L1 expression Negative Weak positive Strong positive Conclusion In a pre-treated nonsquamous NSCLC population with differing PD-L1 expression levels, these initial data suggest activity combining necitumumab and pembrolizumab Besse et al. J Thorac Oncol 216; 11(suppl): abstr MA
43 Immunotherapy in stage IV Studies will analyze role of immunotherapy combinations after PD to immunotherapy However, many studies, many compounds, many combinations may challenge defining guidelines
44 Multimodality approach in non-metastatic tumors Ongoing adjuvant studies with anti-pd1/anti-pdl1 strategies Neoadjuvant trials with immunotherapy planned (promising results in small studies) Major pathologic response in 7/18 (39%) patients treated with 2 doses of nivolumab (Forde ESMO 16) Ongoing studies with consolidation immunotherapy in stage III (PACIFIC, NCT trials) Ongoing studies of integration of CT/RT/immunotherapy (Nicolas-ETOP)
45 Thanks!!!
46 Clinical case
47 Q1. Anti PD-1 or anti PD-L1 drugs given as monotherapy are associated with different iraes; in what percentage of patients do these AEs occur? 1. ~7% 2. ~5% 3. ~25% 4. 5% 15% 5. <5%
48
49 CheckMate 57 iraes Nivolumab (n = 287) Docetaxel (n = 268) Any Grade Grade 3 4 a Any Grade Grade 3 4 a Endocrine, % Hypothyroidism 7 Gastrointestinal, % Diarrhea Hepatic, % ALT increased AST increased Includes events reported in 2.5% of patients. a No grade 5 events were reported at DBL;1 grade 5 event for nivolumab was reported post-dbl. Borghaei H, et al. N Engl J Med. 215;373(17): Pulmonary, % Pneumonitis 3 1 <1 <1 Skin, % Rash Pruritus Erythema Hypersensitivity/Infusion reaction, % Infusion-related reaction <1 < <1 3 3 <1
50 KEYNOTE-1 iraes Herbst RS, et al. Lancet. 216;387(127):
51 Clinical Case, Diagnosis, and Medical History 63 year-old man, smoker (7 pack/year) July 214, diagnosed of lung ADC stage T2N2M1 (bilateral lung metastases, bone metastases, 2 brain mets) NGS-wt SABRT for the brain mets achieving PR Cis/pem 4 cycles with SD, then maintenance pem February 215, PD in lung lesion, bone and brain mets remained in PR
52 Baseline CT (March 16, 215) Nodule in right lower lobe, 42 mm Nonmeasurable lesions, brain mets, bone mets, lung mets, supraclavicular and mediastinal lymph node involvement
53 Clinical Case, Immunotherapy Treatment March 2, 215: Started pembrolizumab C4D1: First evaluation PR C5D1: Maculopapular rash in upper part of both lower extremities (appeared in last week of treatment)
54 54
55 Q2. What skin toxicity is most common with anti PD-1/anti PD-L1 agents? 1. Purpura 2. Maculopapular rash 3. G3 erythema 4. G3 pruritus 5. Stevens-Johnson syndrome
56 Skin Toxicity Incidence Manifestations Note Rash (14%) Pruritus (1%) Low or moderate grade Rash typically focal with a maculopapular appearance occurring on the trunk, back, or extremities Cases of Stevens-Johnson syndrome and toxic epidermal necrosis have been only sporadically reported Some skin reactions occurred in the context of infusion - related reaction Lacouture ME, et al. J Am Acad Dermatol. 214;71(1):
57 How Do We Grade Immune-Related Skin Disorders? Involved body surface area can be evaluated using the rule of nines AE Grade 1 Grade 2 Grade 3 Grade 4 Erythema multiforme Pruritus Purpura Rash maculopap ular Target lesions covering <1% BSA and not associated with skin tenderness Mild or localized Topical intervention indicated Combined area of lesions covering <1% BSA Target lesions covering 1% 3% BSA and associated with skin tenderness Intense or widespread Intermittent Skin changes from scratching (eg, edema, papulation, excoriations, lichenification, oozing/crusts) Oral intervention indicated Limiting instrumental ADL* Combined area of lesions covering 1% 3% BSA Bleeding with trauma Target lesions covering >3% BSA and associated with oral or genital erosions Intense or widespread Constant Limiting self-care ADL* or sleep Oral corticosteroid or immunosuppressive therapy indicated Combined area of lesions covering >3% BSA Target lesions covering >3% BSA Associated with fluid or electrolyte abnormalities ICU care or burn unit indicated *Instrumental ADL refer to preparing meals, shopping for groceries or Spontaneous clothes, using the bleeding telephone, managing money, etc. Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden. Please refer to NCI-CTCAE Macules/papules version 4.3 for definition covering of severity/grade Macules/papules of other skin rashes. National Cancer Institute Common 1% 3% Terminology BSA with Criteria or for Adverse Events (CTCAE) v4.3. covering >3% BSA without symptoms (eg, p and Accessed February 216. Macules/papules covering <1% BSA with or without symptoms (eg, pruritus, burning, tightness) pruritus, burning, tightness) Limiting instrumental ADL* with or without associated symptoms Limiting self-care ADL* - - -
58 How Do We Grade Immune-Related Skin Disorders? Involved body surface area can be evaluated using the rule of nines AE Grade 1 Grade 2 Grade 3 Grade 4 Skin hypopigment ation Stevens- Johnson syndrome Urticaria Hypopigmentation or depigmentation covering <1% BSA No psychosocial impact - - Urticarial lesions covering <1% BSA Topical intervention indicated Hypopigmentation or depigmentation covering >1% BSA Associated psychosocial impact Urticarial lesions covering 1% 3% BSA Oral intervention indicated - - Skin sloughing covering <1% BSA with associated signs (eg, erythema, purpura, epidermal detachment, and mucous membrane detachment) Urticarial lesions covering >3% BSA IV intervention indicated Skin sloughing covering 1% 3% BSA with associated signs (eg, erythema, purpura, epidermal detachment, and mucous membrane detachment) - *Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden. Please refer to NCI-CTCAE version 4.3 for definition of severity/grade of other skin rashes. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v p and Accessed February 216.
59 Time to Onset of First Treatment-Related Select AEs in Nivolumab-Treated Patients in Pooled CheckMate 17/57 a Patients with 1 event from first dose until 3 days post-treatment in a given category were counted only once in the time interval corresponding to the first event, patients with multiple events from categories within the same time interval were counted once in each category. Barlesi F, et al. Ann Oncol. 216;27(suppl 6):abstract 1215PD.
60 Management of Skin Toxicities Grade 1 rash Management strategies Drug therapy/workup Consult Follow-up Study physician Specialist Consider symptomatic treatment including oral antipruritics (eg, diphenhydramine or hydroxyzine) and topical therapy (eg, urea cream) N/A N/A N/A Dose modifications (study drug/study regimen) No dose modifications 1. AZ dosing modification and toxicity management guidelines. 19 August 216 Version. Accessed August 216; 2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines. Prevention and treatment of cancerrelated infections. Version Accessed March 216.
61 Management of Skin Toxicities Grade 2 rash Management strategies Drug therapy/workup Consul t Followup Study physician Specialist General If symptoms improve If symptoms worsen or persist Consider symptomatic treatment including oral antipruritics (eg, diphenhydramine or hydroxyzine) and topical therapy (eg, urea cream) Consider moderate-strength topical steroid If no improvement of rash/skin lesions occurs within 3 5 days or is worsening despite symptomatic treatment and/or use of moderate-strength topical steroid, discuss with study physician Obtain dermatology consult N/A N/A If no improvement of rash/skin lesions occurs within 3 5 days or is worsening despite symptomatic treatment and/or use of moderatestrength topical steroid, promptly start systemic steroids such as prednisone 1 2 mg/kg/day PO or IV equivalent Consider skin biopsy if the event is persistent for >1 2 weeks or recurs Dose modifications (study drug/study regimen) For persistent (>1 2 weeks) Grade 2 events, hold scheduled study drug/study regimen until resolution to Grade 1 or baseline If toxicity worsens then treat as Grade 3 If toxicity improves to Grade 1 or baseline, then resume study drug/study regimen after completion of steroid taper
62 Management of Skin Toxicities Grade 3 and 4 rash Management strategies Drug therapy/workup Consul t Followup Study physician Specialist General If symptoms improve Promptly initiate empiric IV methylprednisolone 1 4 mg/kg/day or equivalent Consider hospitalization Monitor extent of rash (Rule of Nines) Consider skin biopsy (preferably more than 1) as clinically feasible Discuss with study physician If symptoms worsen or N/A persist Dose modifications (study drug/study regimen) Grade 3 Grade 4 Consult dermatology N/A Once the patient is improving, gradually taper steroids over 28 days and consider prophylactic antibiotics, antifungals, and anti-pcp treatment (refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation] 2 ) Hold study drug/study regimen until resolution to Grade 1 or baseline If temporarily holding the study drug/study regimen does not provide improvement of the Grade 3 skin rash to Grade 1 or baseline within 3 days, then permanently discontinue study drug/study regimen Permanently discontinue study drug/study regimen
63 Clinical Case, irae Grade, Management, and Evolution Diagnosis of G2 maculopapular rash After consultation with dermatologist, the patient started oral diphenhydramine and topical therapy (eg, urea cream) It was decided not to administer the anti PD-1/anti PD-L1 therapy and control in 1 week After 1 week, maculopapular rash improved to G1, anti PD- 1/anti PD-L1 treatment was resumed Oct 27, 216: C29D1, pruritus G1
64 Latest CT (January 12, 217) Nodule in right lower lobe, 1 mm Nonmeasurable lesions, lung metastases, supraclavicular and mediastinal lymph nodes, improved; bone and brain mets without changes
Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationESMO 2017 CONGRESS September 2017 Madrid, Spain. Developed in association with the European Thoracic Oncology Platform
Developed in association with the European Thoracic Oncology Platform ESMO 2017 CONGRESS Congress 8 12 September 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationIMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationIMMUNE CHECKPOINT BLOCKADE FOR NSCLC. Marina Chiara Garassino
IMMUNE CHECKPOINT BLOCKADE FOR NSCLC Marina Chiara Garassino Cells of the Immune System Innate immune system: Involving proteins (chemokines and cytokines) and cells, is considered to be the first line
More informationESMO 2018 CONGRESS October 2018 Munich, Germany. Developed in association with the European Thoracic Oncology Platform
Developed in association with the European Thoracic Oncology Platform ESMO 218 CONGRESS 19 23 October 218 Munich, Germany Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationNew Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors
New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationINMUNOTERAPIA II. Dra. Virginia Calvo
INMUNOTERAPIA II Dra. Virginia Calvo LBA53. IMpower130. Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with o without atezolizumab
More informationIASLC 17th World Conference on Lung Cancer
Developed in association with the European Thoracic Oncology Platform IASLC 17th World Conference on Lung Cancer December 4 7, 2016 Vienna, Austria Supported by Eli Lilly and Company. Eli Lilly and Company
More informationCheckpoint inhibitors in the first-line treatment of non-small cell lung cancer
380 Checkpoint inhibitors in the first-line treatment of non-small cell lung cancer L. Decoster, MD 1, K. Vekens, MD 2, S. Mignon, MD 1, D. Schallier, MD, PhD 1, J. De Grève, MD, PhD 1 SUMMARY Antibodies
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationREPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationCarcinoma escamoso: optimizacio n de tratamiento. Noemi Reguart Hospital Clínic Barcelona
Carcinoma escamoso: optimizacio n de tratamiento Noemi Reguart Hospital Clínic Barcelona National Cancer Database (US) 80% 70% 60% 50% 40% 30% Incidence of SCC 27% 20% 10% 0% 1998-1999 2000-2003 2004-2007
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationStato dell arte dell immunoterapia. Il Paziente con NSCLC Francesco Ferraù Oncologia Medica Ospedale S.Vincenzo, Taormina
I CONVEGNO REGIONALE SIFO MEETING DI PRIMAVERA IL FARMACISTA CLINICO E I NUOVI MODELLI DI CURA Taormina, 11/12/13 maggio 217 Stato dell arte dell immunoterapia. Il Paziente con NSCLC Francesco Ferraù Oncologia
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019 DISCLAIMER Not a Substitute for Professional Advice
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationImmunotherapy in Non-Small Cell Lung Cancer
Immunotherapy in Non-Small Cell Lung Cancer Renato G. Martins Stephen H. Petersdorf Endowed Chair in Cancer Care Associate Medical Director, Solid Tumor Adult Oncology, Seattle Cancer Care Alliance Professor,
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationCáncer de pulmón no microcítico
DEFINIENDO LA SECUENCIA O PTIMA DE TRATAMIENTO EN CA NCER AVANZADO Cáncer de pulmón no microcítico Enriqueta Felip Hospital Vall d Hebron, Barcelona Molecular events in NSCLC Adenocarcinoma EGFR-resistance
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More information